Immunology & Autoimmune Deal Benchmarks 2026

Median Upfront

$575M

Range: $304M - $835M

Total Deal Value

$3.0B

Range: $1.9B - $4.2B

Royalty Rate

14% - 23.4%

Tiered up to 27.4%

Dev Milestones

$490M

Range: $315M - $668M

Model Your Deal

Market Analysis

The immunology and autoimmune licensing market in 2026 is defined by fierce competition among biologics, JAK inhibitors, and next-generation targeted therapies. Phase 2 monoclonal antibody deals for autoimmune indications carry a median total deal value of $3.0B, with upfront payments ranging from $304M to $835M. SLE/lupus remains one of the most actively pursued indications given the large unmet medical need and limited approved biologics.

Deal structures in autoimmune licensing reflect the breadth of indication expansion potential. Development milestones average $490M, while commercial milestones of $1.1B reward multi-indication lifecycle strategies. The ability to demonstrate differentiation from entrenched TNF and IL-6 therapies is the single largest driver of premium valuations.

Royalty rates for immunology deals settle between 14% and 23.4% at the base tier, with escalation to 27.4% on blockbuster sales. Deals featuring novel mechanisms targeting B-cell depletion, T-regulatory cell modulation, or cytokine-specific pathways command the highest premiums relative to follow-on JAK or IL-targeting agents.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are the key trends shaping immunology deal activity in 2026?

Immunology deal activity is driven by the shift from broad immunosuppression to targeted pathway modulation. Deals for novel mechanisms such as anti-TYK2, anti-TSLP, and CAR-T for autoimmune disease are commanding premium terms. Phase 2 autoimmune assets average $3.0B total deal value, with strong licensee demand for differentiated safety profiles.

How do JAK inhibitor deals compare to biologic deals in autoimmune indications?

JAK inhibitor deals generally carry lower upfront payments than biologic deals due to safety label concerns (boxed warnings) and competitive density. However, next-generation selective JAK1 inhibitors with improved safety data are closing the gap. Biologic deals for autoimmune indications average $575M median upfront versus 15-25% lower for JAK inhibitors.

How large is the autoimmune disease deal market?

The global autoimmune therapeutics market exceeds $130 billion, making it one of the largest therapeutic categories for licensing activity. SLE/lupus, rheumatoid arthritis, psoriasis, and inflammatory bowel disease collectively drive the majority of deal volume. The continued emergence of novel targets (TYK2, CD19 CAR-T, TSLP) ensures a robust pipeline of dealmaking opportunities.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Immunology & Autoimmune Deal Benchmarks 2026

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Dermatology Deal Overview

Gastroenterology Deal Overview

IL-17 Inhibitor Deals

JAK Inhibitor Deals

Ready to Calculate Your Deal Terms?